Ebola Virus Net is the web resource for anyone interested in ebola. Ebola (Ebola hemorrhagic fever), is a severe, often fatal disease in humans and nonhuman primates such as monkeys, gorillas, and chimpanzees. Ebola is a rare and deadly disease caused by infection with a virus of the family Filoviridae, genus Ebolavirus. There are five identified Ebolavirus species, four of which have caused disease in humans. Ebola is found in several African countries. The first Ebola species was discovered in 1976 near the Ebola River in the Democratic Republic of the Congo. Since then, outbreaks have appeared sporadically in Africa. The largest outbreak to date was the epidemic in West Africa, which occurred from December 2013, to January 2016, with 28,646 cases and 11,323 deaths. Other outbreaks in Africa began in the Democratic Republic of the Congo in May 2017 and 2018. In July 2019, the World Health Organization declared the Congo Ebola outbreak a world health emergency.

When an infection does occur in humans, the virus can be spread to others through direct contact with the blood or body fluids of a person who is sick with Ebola, or through contact with objects that have been contaminated with the blood or body fluids of an infected person. Until recent, no vaccines were effective. In December 2016, Ebola was found to be 70–100% prevented by rVSV-ZEBOV vaccine, making it the first proven vaccine against the disease. More than 100,000 people have been vaccinated against Ebola as of 2019.

The objectives of Ebola Virus Net are to be the public and professional information resource for ebola and to serve as a network in the exchange of information and news related to ebola.

• Lessons Learned from Ebola and Natural Disasters Help Federal Agencies' COVID-19 Response - HS Today - HSToday
  Mon, 27 Jun 2022 12:11 GMT
• Eyes a haven for Ebola and other viruses - Ophthalmology Times
  Fri, 24 Jun 2022 07:00 GMT
• New technology may enable rapid diagnosis of Ebola virus - News-Medical.Net
  Wed, 08 Jun 2022 07:00 GMT
• Ghana denies Ebola case, says simulation drill was behind confusion - Africa Times
  Wed, 22 Jun 2022 16:11 GMT
• Harnessing Changes in Light, WUSTL, U of Michigan Researchers Developing Ebola Test - 360Dx
  Fri, 24 Jun 2022 14:49 GMT
• UNICEF DRC Ebola Situation Report #6 for 26 May - 01 June 2022 - Democratic Republic of the Congo - ReliefWeb
  Fri, 03 Jun 2022 07:00 GMT
• Ebola Vaccine Market Future Business Scope 2022-2028 | Merck and Company, Janssen Pharmaceutica NV, GlaxoSmithKline - Digital Journal
  Mon, 27 Jun 2022 10:46 GMT
• How does one study a deadly virus? Carefully. - Scope
  Mon, 27 Jun 2022 16:00 GMT
• Ebola virus disease - Democratic Republic of the Congo - World Health Organization
  Thu, 28 Apr 2022 07:00 GMT
• #Ghana Has Not Recorded Any Cases of an #Ebola Outbreak, Said a Senior #health ... - Latest Tweet by IANS - LatestLY
  Thu, 23 Jun 2022 07:12 GMT
• Ebola Vaccine Market Analysis, Size, Current Scenario and Future Prospects –Merck, Johnson and Johnson, CanSino Biologics Inc – Designer Women - Designer Women
  Wed, 22 Jun 2022 05:10 GMT
• Chemically modified plant compounds work against hepatitis E virus - Science Daily
  Mon, 27 Jun 2022 16:39 GMT
• MSU researchers use AI to stay ahead of COVID-19 and other diseases - MSUToday
  Mon, 27 Jun 2022 18:07 GMT
• Ebola virus hides out in brain - ASBMB Today
  Sun, 17 Apr 2022 04:56 GMT
• Democratic Republic of the Congo declares Ebola outbreak over - WHO | Regional Office for Africa
  Thu, 16 Dec 2021 08:00 GMT

• PRO/AH/EDR> Ebola update (44): Burkina Faso ex Cote d'Ivoire, 2nd case, NOT
  Mon, 30 Aug 2021 11:01:25 -0400
  Ebola -- Burkina Faso
  On 22 Aug 2021, the Ministry of Health informed the population of the admission to the Medical Emergencies of the Bogodogo University Hospital (CHU-B) of a 22-year-old patient who had stayed in the Republic of [Cote d'Ivoire]. The diagnostic procedure consisted of sampling analysis at the National Reference Laboratory for Viral Haemorrhagic Fever (LNR-FHV at the Muraz Centre) and the Pasteur Institute of Dakar for confirmation. The results obtained make it possible to permanently rule out

• Recombinant vesicular stomatitis vaccine against nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential Mon, 27 Jun 2022 06:00:00 -0400
  Nipah virus (NiV) disease is a bat-borne zoonosis responsible for outbreaks with high lethality and is a priority for vaccine development. With funding from the Coalition of Epidemic Preparedness Innovations (CEPI), we are developing a chimeric vaccine (PHV02) composed of recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoproteins of both Ebola virus (EBOV) and NiV. The EBOV glycoprotein (GP) mediates fusion and viral entry and the NiV attachment glycoprotein (G) is a...
• Strengthening vaccines and medicines manufacturing capabilities in Africa: challenges and perspectives Mon, 27 Jun 2022 06:00:00 -0400
  Africa carries a high burden of infectious diseases. Every year, millions of Africans contract tuberculosis, malaria, and many other diseases. Malaria kills hundreds of thousands of children under the age of five years annually. More than 11,000 people died during the 2014-2016 Ebola outbreak in West Africa; still, occasional cases of Ebola, as well as monkeypox, periodically appear in the Democratic Republic of Congo. Since most of the African countries gained their independence during the...
• Ebola virus outbreak returns to the Democratic Republic of Congo: An urgent rising concern Mon, 27 Jun 2022 06:00:00 -0400
  On April 23, 2022, the Ministry of Health of the Democratic Republic of the Congo announced an EVD outbreak after discovering 2 confirmed cases and identifying 267 contacts. With collaboration from the WHO, the MoH are taking many interventions to prevent further expansion of this outbreak. Forty-six years ago, the Ebola virus was first discovered in 1976 near the Ebola River in the DRC. Since then, 13 outbreaks of EVD have occurred in the DRC and, in 2020, it witnessed the second largest EVD...
• A sequential test for assessing the effectiveness of response strategies during an emerging epidemic Mon, 27 Jun 2022 06:00:00 -0400
  In epidemiology, the fatality rate is an important indicator of disease severity and has been used to evaluate the effects of new treatments. During an emerging epidemic with limited resources, monitoring the changes in fatality rate can also provide signals on the evaluation of government policies and healthcare quality, which helps to guide public health decision. A statistical test is developed in this paper to detect changes in fatality rate over time during the course of an emerging...
• Comparative value-based pricing of an Ebola vaccine in resource-constrained countries based on cost-effectiveness analysis Fri, 24 Jun 2022 06:00:00 -0400
  CONCLUSION: Despite the concerns with the cost-effectiveness-based approach, we illustrated that it is an easily comprehensible method for determining the VBP of a vaccine using a cost-effectiveness analysis. Choice of data, population characteristics, and disease dynamics among factors that need to be considered when comparisons are made across countries.
• Ophthalmic sequelae and psychosocial impact in pediatric ebola survivors Fri, 24 Jun 2022 06:00:00 -0400
  BACKGROUND: Ebola virus disease (EVD) outbreaks in West Africa (2013-2016) and the Democratic Republic of Congo (2018-2020) have resulted in thousands of EVD survivors who remain at-risk for survivor sequelae. While EVD survivorship has been broadly reported in adult populations, pediatric EVD survivors are under-represented. In this cross-sectional study, we investigated the prevalence of eye disease, health-related quality-of-life, vision-related quality-of-life, and the burden of mental...
• Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity Fri, 24 Jun 2022 06:00:00 -0400
  Molnupiravir is a β-d-N4-hydroxycytidine-5'-isopropyl ester (NHC) compound that exerts antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses. Thus, the repurposing of Molnupiravir has gained significant attention for combatting infection with SARS-CoV-2, the etiological agent of COVID-19. Recently, Molnupiravir was granted authorization for the treatment of mild-to-moderate COVID-19 in adults. Findings from in vitro experiments, in vivo studies and clinical...
• Natural History of Sudan ebolavirus to Support Medical Countermeasure Development Fri, 24 Jun 2022 06:00:00 -0400
  Sudan ebolavirus (SUDV) is one of four members of the Ebolavirus genus known to cause Ebola Virus Disease (EVD) in humans, which is characterized by hemorrhagic fever and a high case fatality rate. While licensed therapeutics and vaccines are available in limited number to treat infections of Zaire ebolavirus, there are currently no effective licensed vaccines or therapeutics for SUDV. A well-characterized animal model of this disease is needed for the further development and testing of vaccines...
• NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans Fri, 24 Jun 2022 06:00:00 -0400
  Natural killer cells play an important role in the control of viral infections both by regulating acquired immune responses and as potent innate or antibody-mediated cytotoxic effector cells. NK cells have been implicated in control of Ebola virus infections and our previous studies in European trial participants have demonstrated durable activation, proliferation and antibody-dependent NK cell activation after heterologous two-dose Ebola vaccination with adenovirus type 26.ZEBOV followed by...
• Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic Fri, 24 Jun 2022 06:00:00 -0400
  Intravenous (IV) administration of antiviral monoclonal antibodies (mAbs) can be challenging, particularly during an ongoing epidemic, due to the considerable resources required for performing infusions. An ebolavirus therapeutic administered via intramuscular (IM) injection would reduce the burdens associated with IV infusion and allow rapid treatment of exposed individuals during an outbreak. Here, we demonstrate how MBP134, a cocktail of two pan-ebolavirus mAbs, reverses the course of Sudan...